PYPD

PolyPid Ltd.
CAPPED RATING

PolyPid Ltd. (PYPD) is rated C- (2.1/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B+); its weakest is Growth (F). The rating has held at C- for 2 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.1 / 5.0
C-
Value
C+
Factor Score 2.5 / 5.0
Growth
F
Factor Score 0.5 / 5.0
Profitability
D
Factor Score 1.3 / 5.0
Momentum
B+
Factor Score 3.7 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -6.5
EV / EBITDA -4.2
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M 31.2%
Price Return 12M 66.9%
Catalyst Signal 0.00
Market Cap $127.2M
TTM Revenue N/A
Price / Sales N/A
ROE -243.6%

Historical Factor Score Progression

Held C- for 2 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-14 C+ (2.5) F (0.5) D (1.3) B+ (3.7) C+ (2.6) C- (2.1)
2026-11-07 C+ (2.5) F (0.3) D (1.3) B+ (3.7) C+ (2.7) C- (2.1)
2026-10-31 C+ (2.5) F (0.3) D (1.4) B+ (3.8) C+ (2.7) C- (2.1)
2026-10-24 C+ (2.5) F (0.7) D (1.3) B+ (3.7) C+ (2.6) C (2.2)
2026-10-17 C+ (2.5) F (0.7) D (1.3) C+ (2.8) C+ (2.6) C- (2.0)
Page 1 of 4